Monogram Biosciences is a life sciences company committed to advancing personalized medicine and improving patient outcomes through the development of innovative products that guide and target the most appropriate treatments. Through a comprehensive understanding of genetic structures and the biology and pathology of disease, the company has pioneered and is developing molecular diagnostics and laboratory services that are intended to:
enable physicians to better manage infectious diseases and cancer by providing the critical information that helps them prescribe personalized treatment for patients by matching the underlying molecular features of an individual patient's disease to the drug expected to have maximal therapeutic benefit
enable pharmaceutical companies to develop new and improved anti-viral therapeutics and targeted cancer therapeutics while minimizing development costs by accelerating the progress of existing drugs in development through clinical trials.
Over the last several years, the company has built a business based on the personalized medicine approach in HIV drug resistance testing. Through its merger with Aclara BioSciences, Inc. in December 2004, the company intends to leverage the experience and infrastructure that it has built in the HIV market to the substantially larger market opportunity of cancer-testing products utilizing the proprietary VeraTag technology, formerly known as eTag technology. Monogram Biosciences was formerly known as ViroLogic, Inc. It changed its name to Monogram Biosciences, Inc. in 2005. The company was incorporated in Delaware in 1995 and is headquartered in South San Francisco, CA.